



A Meeting of the **Borders Area Drugs and Therapeutics Committee** held at 12:30pm on
Wednesday, 26th May 2021 via Microsoft Teams
MINUTE

Present:- Alison Wilson (Director of Pharmacy) (Chair) (AW); Keith Maclure (Lead Pharmacist – Medicines Utilization & Planning) (KMacl); Adrian Mackenzie (Lead Pharmacist Community) (AMack); Dr Nicola Henderson (GP) (NH); Keith Allan (Public Health Consultant) (KA); Liz Leitch, Formulary Pharmacist (LL); Andrew Leitch (Lay Member) (AL); Kate Warner (Minute Secretary) (KW)

Item	Situation Background; Assessment	Recommendation	Person	Timescale
1.	Apologies and Announcements: Dr Ed James; Cathryn Park; Rhona Morrison; Effie Dearden (DME Consultant) Guest: later in meeting - Ann O Connor, Dietician BGH – prescribing course			
2.	Declarations of Interest: None			
3.	DRAFT Minute previous meeting			
3.1	Draft minute from 20 th January 2021 meeting was approved as an accurate record of the meeting with 4.2 below discussed at this point.	ADTC Approved; upload to website	KW	27/05/2021
4.	Matters Arising			
4.1	Update for East Regional Formulary included at item 8.1 from Jane Browning			
4.2	LL requested that there was clear agreement documented on the correct process for the approval of Shared Care Protocols as the recent approval of Guanfacine SCP had been delayed. ADTC agreed that Shared Care Protocols should go to Clinical Interface Group first for approval and then to ADTC due to inclusion of drug/treatment for final approval.	Discuss with Chair of Clinical Interface Group to ensure all know the route for approval of SCPs.	AW	30/06/2021
5.	NEW MEDICINE APPLICATIONS:			
5.1	None			
6.	PATIENT & MEDICINES SAFETY:			
6.1	Datix Review – no report as RM was unable to attend at short notice. A short summary to accompany the Agenda in future was requested. AW commented on current work at ward level by RM on medicines safety and review of missed doses.	Include summary of Datix in agenda in future	RM/KW	On-going
7.	CLINICAL POLICIES, PROCEDURES and GUIDELINES for APPROVAL:			

7.1	ADTC discussed the updated version of Treatment of depression pathway tabled by Kyna Harvey, Mental Health Clinical Pharmacist. Previously called Guidance for initiating anti-depressant therapy (#2228 on intranet). Links included for self-help, primary and secondary care services available from NHS Borders. ADTC agreed that the document is informative and useful; GP commented that the pyramid structure and pathway for treating depression is good for GPs to be able to see all resources and non-prescribing options. ADTC raised a concern about the medicine choices not being the same as Borders Joint Formulary choices. Reasons and papers had been supplied with agenda for the reasons for these changes; other Board choices were discussed and guidance on cost effectiveness and efficacy. ADTC agreed that the drug choices must come to Borders Formulary Committee as New Medicines Applications to be discussed there along with evidence and prescribing data.	Prescribing data reports – work with Kyna H NMA form to Kyna H for BFC agenda Add to BFC agenda June	KMacI LL/KW KW	
7.2	ADTC noted that the Approved List for NHS Pharmacy First Scotland was closed and that suggestions had been sent from Board and also community pharmacists on Contractors Committee and Area Pharmaceutical Committee. Once collated this will be forwarded to local ADTCs; the introduction of list pushed back to 1 st October.	ADTC noted		
7.3	ADTC Annual Report 2020-21; to include in the Pharmacy Annual Report and upload to Medicines microsite/NHSB website.	ADTC Approved Upload to web	KW	31/05/2021
8.	FOR INFORMATION and NOTING:			
8.1	East Regional Formulary update – project team continue to work on putting governance in place now supported by all Boards; in Borders this was discussed at Board Executive Team 21 st April 2021. Senior consultants are supportive of the regional approach to formulary and also to joining the chapter working groups, incorporating practice and adapting as appropriate. ADTC supports the need for ERF project to move swiftly; resource requirements for chapter work discussed at BET and there is a risk register as part of the project.	ADTC Noted Update EJ and ED on progress	AW	30/06/2021
8.2	Lothian Formulary App is available to view as an example of how the East Regional Formulary will look – this is not our current formulary.	ADTC Noted		
8.3	ADTC discussed products coming through SMA as paediatric licence extensions and how they should be handled locally. ADTC agreed that if they are already on the Borders Formulary, would have extended approval for paediatric use here and as they come from SMC, formulary pharmacist will inform the local lead of the extension and they can agree to include in local formulary.	ADTC Noted		
8.4	ADTC noted and approved use of a new script for breast cancer patients starting on adjuvant zoledronic acid which has been adapted for use at BGH by Cancer Specialist Pharmacists led by Dr C Bedi as part of chemotherapy protocols.	ADTC Noted		
8.5	ADTC noted and approved use of the updated Midwife Exemptions; in accordance with the Scottish National Midwifery Formulary. Midwives can use and supply the products for women under their care under their own professional licence.	ADTC Noted		

8.6	Minor updates to Insulin Dose Adjustment Policy – approval received via email.	ADTC Noted		
8.7	PGD for the supply and administration of Specified Bowel Preparation Products to Adult Patients undergoing Colon Capsule Endoscopy (CCE) NHS Borders – changes approved by ADTC by email 06/04/21 with comments and changes requested made (Karen Maitland)	ADTC Noted		
8.8	NHS Borders Hospital Antimicrobial Point Prevalence Survey 2020	ADTC Noted		
8.9	Update regarding Steroid Emergency Card	ADTC Noted		
8.10	Scottish Government delivery plan in relation to the Independent Medicines and Medical Devices Safety Review; published on the Scottish Government's website.	ADTC Noted		
8.11	ADTC noted MHRA advice about the Astra Zeneca COVID 19 vaccine and thromboembolic events with concurrent low platelet counts – revisions to product information. Locally, procedures are in place for clinics to adhere to this.	ADTC Noted		
8.12	Guide by PHE to support decision making on whether patients can receive the AZ vaccine or should receive an alternative vaccine.	ADTC Noted		
9.	FEEDBACK from SUB GROUPS			
9.1	Borders Formulary Committee DRAFT Minute – meeting held 28 th April 2021	ADTC Noted		
9.2	Antimicrobial Management Team DRAFT Action Tracker held 21 st April 2021	ADTC Noted		
9.3	Anticoagulant Committee DRAFT Minute –meeting held 29 th January 2021 LL reported that the GP on committee will be retiring at the end of March and a new GP member is being sought, who may have an interest in anticoagulants and/or being part of the committee. Committee meets up to 4 times a year.	ADTC Noted Feedback to LL any GP interest in joining	NH	30/06/2021
9.4	IV Therapy Group DRAFT Minute – meeting held 12 th May 2021	ADTC Noted		
9.5	Tissue Viability Steering Group – no recent meeting			
9.6	Wound Formulary Group DRAFT Minute – no recent meeting			
9.7	NHS Lothian ADTC Minute – meetings held 5 th February 2021; 26 th March 2021; next meeting 4 th June 2021. LL	ADTC Noted		
10.	AOCB			
10.1	NFR – Oxymethalone was discussed and decision details saved in NFR folder	Letter to applicant	KW	27/05/2021
Date and time of next meeting: 28th July 2021 at 12:30pm via Microsoft Teams.				